Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma

BACKGROUND: Immune checkpoint blockades (ICBs) are a promising treatment for cancers such as melanoma by blocking important inhibitory pathways that enable tumor cells to evade immune attack. Programmed death ligand 1 monoclonal antibodies (aPDL1s) can be used as an ICB to significantly enhance the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hei, Yu, Teng, Binhong, Zeng, Ziqian, Zhang, Siqi, Li, Qian, Pan, Jijia, Luo, Zuyuan, Xiong, Chunyang, Wei, Shicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082626/
https://www.ncbi.nlm.nih.gov/pubmed/32214807
http://dx.doi.org/10.2147/IJN.S225807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082626/
https://www.ncbi.nlm.nih.gov/pubmed/32214807
http://dx.doi.org/10.2147/IJN.S225807

Ejemplares similares